00656-2/asset/38c98550-9ec2-44e8-ba6a-dbb815075666/main.assets/gr1_lrg.jpg)
surmount-1 tirzepatide trial obesity without diabetes for maintenance of bodyweight reduction in people with in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled Presented at ECO 2025: In
Description
We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 51 million people across the globe
I wont lie, it was a little painful, but totally worth it
Will I regain if I stop
Retatrutide incorporates a fatty acid modification to enhance its stability and extend its half-life to six days, enabling weekly dosing [16]
The prolonged half-life allows for once-weekly administration in humans [1]
